New ways to treat bacterial infections

Drug Discovery Today

Volumn 7, Issue 21, 2002, Pages 1086-1091

  Taylor, Peter W ^a   Stapleton, Paul D ^a   Paul Luzio, J ^b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BACTERIAL ENZYME; BACTERIOCHLORIN; BETA LACTAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CHLORAMPHENICOL ACETYLTRANSFERASE; CLAVULANIC ACID; DOXYCYCLINE; EPICATECHIN GALLATE; EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; MESSENGER RNA; METICILLIN; OLIGORIBONUCLEOTIDE; OXACILLIN; PENICILLIN BINDING PROTEIN; PENICILLIN G; PEPTIDOGLYCAN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE; PORPHYRIN; RIBONUCLEASE P; SUCCINIC ACID DERIVATIVE; TEICOPLANIN; TETRACYCLINE DERIVATIVE; TETRAZOLE DERIVATIVE; VACCINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIOPHAGE; CHEMICAL MODIFICATION; COST OF ILLNESS; DRUG POTENCY; GENOTYPE; HELICOBACTER PYLORI; HOSPITAL COST; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; PHENOTYPE; PHOTOSENSITIZATION; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; PHOTOSENSITIZING AGENTS;

EID: 0036848468     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02498-4     Document Type: Review

References (50)

1. Williams R. Resistance as a worldwide problem. Lewis K., et al. Bacterial Resistance to Antimicrobials. 2002;223-238 Marcel Dekker.
2. Report by the Comptroller and Auditor General of the National Audit Office (2000) The Management and Control of Hospital Acquired Infection in Acute NHS Trusts in England, pp. 17-21, UK Stationery Office
3. Vaira D., et al. Helicobacter pylori infection from pathogenesis to treatment - a critical appraisal. Aliment. Pharmacol. Ther. 16:2002;S105-113.
4. Kerr K.G., Lacey R.W. Why do we still get epidemics? Hunter P.A., et al. Fifty Years of Antimicrobials: Past Perspectives and Future Trends. 1995;179-203 Cambridge University Press.
5. Gopal Rao G. Risk factors for the spread of antibiotic-resistant bacteria. Drugs. 55:1998;323-330.
6. Centers for Disease Control . Staphylococcus aureus resistant to vancomycin. MMWR. 51:2002;565-567.
7. British National Formulary 44, September 2002, pp.258-329, British Medical Association and the Royal Pharmaceutical Society of Great Britain
8. Barrett J.F. Encourage research and product development. Avorn J.L., et al. Antibiotic Resistance: Synthesis of Recommendations by Expert Policy Groups. 2001;53-64 World Health Organisation.
9. Tan Y.-T., et al. Molecular strategies for overcoming antibiotic resistance in bacteria. Mol. Med. Today. 6:2000;309-314.
10. Neu H.C., et al. Amoxycillin/clavulanic acid: a review of its efficacy in over 38 500 patients from 1979 to 1992. J. Chemother. 5:1993;67-93.
11. Simpson I., et al. Effects of following National Committee for Clinical Laboratory Standards and Deutsche Industrie Norm-Medicinische Mikrobiologie guidelines, country of isolate origin, and site of infection on susceptibility of Escherichia coli to amoxicillin-clavulanate (Augmentin). J. Clin. Microbiol. 36:1998;1361-1365.
12. Toney J.H., et al. Antibiotic sensitization using biphenyl tetrazoles as potent inhibitors of Bacteriodes fragilis metallo-β-lactamase. Chem. Biol. 5:1998;185-196.
13. Toney J.H., et al. Structure-activity relationships of biphenyl tetrazoles as metallo-β-lactamase inhibitors. Bioorg. Med. Chem. Lett. 9:1999;2741-2746.
14. Toney J.H., et al. Succinic acids as potent inhibitors of plasmid-borne IMP-1 metallo-β-lactamase. J. Med. Chem. 276:2001;31913-31918.
15. Hamilton-Miller J.M.T. Antimicrobial properties of tea (Camellia sinensis L.). Antimicrob. Agents Chemother. 39:1995;2375-2377.
16. Yam T.S., et al. The effect of a component of tea (Camellia sinensis) on methicillin resistance, PBP2′ synthesis, and β-lactamase production in Staphylococcus aureus. J. Antimicrob. Chemother. 42:1998;211-216.
17. Brakstad O.G., Maeland J.A. Mechanisms of methicillin resistance in staphylococci. APMIS. 105:1997;264-276.
18. Shiota S., et al. Marked reduction in the minimum inhibitory concentration (MIC) of β-lactams in methicillin-resistant Staphylococcus aureus produced by epicatechin gallate, an ingredient of green tea (Camellia sinensis). Biol. Pharm. Bull. 22:1999;1388-1390.
19. Hamilton-Miller J.M.T., Shah S. Activity of the tea component epicatechin gallate and analogues against methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 46:2000;852-853.
20. Zhao W.-H., et al. Mechanism of synergy between epigallocatechin gallate and β-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45:2001;1737-1742.
21. Stapleton, P.D. et al. (2002) Mechanism of methicillin resistance modulation in Staphylococcus aureus by epicatechin gallate. Intersci. Conf. Antimicrob. Agents Chemother. (Abstract C1.1061)
22. Nicolson K., et al. Potentiation of methicillin activity against methicillin-resistant Staphylococcus aureus by diterpines. FEMS Microbiol. Lett. 179:1999;233-239.
23. Chiosis G., Boneca I.G. Selective cleavage of D-ala-D-lac by small molecules: re-sensitizing resistant bacteria to vancomycin. Science. 293:2001;1484-1487.
24. Renau T.E., et al. Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorg. Med. Chem. Lett. 12:2002;763-766.
25. Nelson M.L., Levy S.B. Reversal of tetracycline resistance mediated by different bacterial tetracycline resistance determinants by an inhibitor of the Tet(B) antiport protein. Antimicrob. Agents Chemother. 43:1999;1719-1724.
26. Guerrer-Takada C., et al. Phenotypic conversion of drug-resistant bacteria to drug sensitivity. Proc. Natl. Acad. Sci. U. S. A. 94:1997;8468-8472.
27. Taylor P.W. Antibiotic influence on the susceptibility of Gram-negative bacteria to complement. Chemioterapia. 4:1985;S542-543.
28. Gemmell C.G. Antibiotics and the immune system. O'Grady F., et al. Antibiotic and Chemotherapy. 7th edn:1997;125-130 Churchill Livingstone.
29. Dubos R., Avery O.T. Decomposition of the capsular polysaccharide of pneumococcal type III by a bacterial enzyme. J. Exp. Med. 54:1931;51-71.
30. Avery O.T., Dubois R. The protective action of a specific enzyme against type III pneumococcus infection in mice. J. Exp. Med. 54:1931;73-89.
31. Goodner K., et al. The action of a specific enzyme upon the dermal infection of rabbits with type III pneumococcus. J. Exp. Med. 55:1932;393-404.
32. Taylor, P.W. (1987) Enzymatic Detection of Bacterial Capsular Polysaccharide Antigens. USP4695541
33. Eftekar F., Speert D.P. Alginase treatment of mucoid Pseudomonas aeruginosa enhances phagocytosis by human monocyte-derived macrophages. Infect. Immun. 56:1988;2788-2793.
34. Wainwright M. Photodynamic antimicrobial chemotherapy (PACT). J. Antimicrob. Chemother. 42:1998;13-28.
35. Dougherty T.J., et al. Photodynamic therapy. J. Natl. Cancer Inst. 90:1998;889-905.
36. Levy J.G. Photodynamic therapy. Trends Biotechnol. 13:1995;14-18.
37. Wilson M., Pratten J. Lethal photosensitisation of Staphylococcus aureus in vitro: effect of growth phase, serum, and pre-irradiation time. Lasers Surg. Med. 16:1995;272-276.
38. Wilson M., et al. Killing of Streptococcus sanguis in biofilms using a light-activated antimicrobial agent. J. Antimicrob. Chemother. 37:1996;377-381.
39. Nitzan Y., et al. Structure-activity relationship of porphines for photoinactivation of bacteria. Photochem. Photobiol. 62:1995;342-347.
40. Merchat M., et al. Meso-substituted cationic porphyrins as efficient photosensitizers of Gram-positive and Gram-negative bacteria. J. Photochem. Photobiol. B. 32:1996;153-157.
41. Minnock A., et al. Photoinactivation of bacteria. Use of a cationic water-soluble zinc phthalocyanine to photoinactivate both Gram-negative and Gram-positive bacteria. J. Photochem. Photobiol. B. 32:1996;159-164.
42. Wilson M., et al. Effect of blood on lethal photosensitization of bacteria in subgingival plaque from patients with chronic periodontitis. Lasers Med. Sci. 8:1993;297-303.
43. Soukos N.S., et al. Targeted antimicrobial photochemotherapy. Antimicrob. Agents Chemother. 42:1998;2595-2601.
44. Millson C.E., et al. Ex vivo treatment of gastric Helicobacter infection by photodynamic therapy. J. Photochem. Photobiol. B. 32:1996;59-65.
45. Szpakowska M., et al. Susceptibility of Pseudomonas aeruginosa to a photodynamic effect of the arginine hematoporphyrin derivative. Int. J. Antimicrob. Agents. 8:1997;23-27.
46. Alisky J., et al. Bacteriophages show promise as antimicrobial agents. J. Infect. 36:1998;5-15.
47. Summers W.C. Bacteriophage therapy. Annu. Rev. Microbiol. 55:2001;437-451.
48. Sulakvelidze A., et al. Bacteriophage therapy. Antimicrob. Agents Chemother. 45:2001;649-659.
49. Merril C.R., et al. Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. U. S. A. 93:1996;3188-3192.
50. Slopek S., et al. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch. Immunol. Ther. Exp. 35:1987;569-583.